A short History

Pharmaleads in a few dates

Dec. 2000 : incorporation of Pharmaleads by the two founding scientists, Professors Bernard Roques and Marie-Claude Fournié-Zaluski

Jan. 2004 : two new founding managers, Thierry Bourbié and Jean-Pierre Rogala, joined the Company

2005-2008 : iXCore buys into the capital of Pharmaleads investing €4 million over 4 years

Dec. 2005 : signature of its first non-exclusive license for the quantification of botulinum toxin (for application in the medical and cosmetic domain)

Aug 2006 : the network of surveillance laboratories over French territory is equipped with the EzyBot® field case

Oct. 2008 : signature of an exclusive license for the its lead pain molecule with the Swiss Company Debiopharm

Ap. 2012 : Nature Reviews Drug Discovery (NRDD) published an article by Pharmaleads top scientists on DENKIS

Today, Pharmaleads is fully dedicated to the clinical and pre-clinical development of its proprietary molecules for the treatment of severe pain.